India Withdraws Controversial Drug Price Curb Clause
This article was originally published in PharmAsia News
Executive Summary
Its ‘Advantage’ Indian drug industry as the national pricing watchdog withdraws a vexatious guideline that empowered it to impose price controls on a large set of products.